BioMedNewsBreaks

WednesdayFeb 18, 2026 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing focus in biotech mergers and acquisitions on de-risked, late-stage assets with clinical validation. The article, titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” examines how pharmaceutical companies and investors are prioritizing programs with established safety and efficacy data, placing companies such as Oncotelic, with multiple clinical- and late-stage oncology and central nervous system programs, in alignment with current M&A trends as it advances its…

Continue Reading

WednesdayFeb 18, 2026 9:20 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal therapeutic targeting post-traumatic stress disorder. The application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” includes composition and method claims and expands Silo’s intellectual property portfolio in stress-modulating therapeutics within a key international market, with management noting the allowance supports protection of the Company’s core scientific innovations ahead…

Continue Reading

TuesdayFeb 17, 2026 2:40 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway 

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and…

Continue Reading

TuesdayFeb 17, 2026 10:45 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Announces Governance and Capital Structure Initiatives to Advance Institutional Readiness

Earth Science Tech (OTC: ETST) announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. Building on approximately $3.3 million in net income for fiscal 2025 and anticipated $1.4 million in cost savings in fiscal 2026, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation, introduce advisory shareholder votes on executive compensation and Series B Preferred Stock retirement, rationalize its capital structure and reduce executive and board compensation, as management positions the company for disciplined growth and improved…

Continue Reading

TuesdayFeb 17, 2026 10:35 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages Semple, Marchal & Cooper as New PCAOB Auditor

Earth Science Tech (OTC: ETST) announced it has engaged Semple, Marchal & Cooper LLP as its new independent Public Company Accounting Oversight Board auditor, citing the need to strengthen its financial governance framework as operations expand across pharmacy compounding, telemedicine and real estate. The board determined that the firm’s broader resources and multidisciplinary expertise align with the company’s growing operational complexity, supporting enhanced auditing efficiencies and oversight as ETST continues scaling its diversified health and wellness portfolio. To view the full press release, visit https://ibn.fm/hEaGE About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company,…

Continue Reading

TuesdayFeb 17, 2026 10:25 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal Q3 2026 Revenue Up 14% and Net Income Up 341%

Earth Science Tech (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and…

Continue Reading

TuesdayFeb 17, 2026 10:15 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers. To view the full press release, visit https://ibn.fm/lcSDZ About…

Continue Reading

TuesdayFeb 17, 2026 10:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company’s vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company’s profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform. To view the full press release, visit https://ibn.fm/iSd01 About Earth Science Tech, Inc. Earth Science Tech, Inc.…

Continue Reading

TuesdayFeb 17, 2026 9:30 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models

Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that Telomir-Zn reduces labile redox-active iron while increasing zinc availability, targeting the elevated iron levels and oxidative stress observed in many triple-negative breast cancer tumors. To view the full press release, visit https://ibn.fm/CHKT9 About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing…

Continue Reading

TuesdayFeb 17, 2026 9:26 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products 

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio.  To view the full press release, visit https://ibn.fm/2YOl8  About Nutriband Inc.  We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch…

Continue Reading